Reprogramming the constant region of immunoglobulin g subclasses for enhanced therapeutic potency against cancer

Tae Hyun Kang, Sang Taek Jung

Research output: Contribution to journalReview article

Abstract

The constant region of immunoglobulin (Ig) G antibodies is responsible for their effector immune mechanism and prolongs serum half-life, while the fragment variable (Fv) region is responsible for cellular or tissue targeting. Therefore, antibody engineering for cancer therapeutics focuses on both functional efficacy of the constant region and tissue-or cell-specificity of the Fv region. In the functional aspect of therapeutic purposes, antibody engineers in both academia and industry have capitalized on the constant region of different IgG subclasses and engineered the constant region to enhance therapeutic efficacy against cancer, leading to a number of successes for cancer patients in clinical settings. In this article, we review IgG subclasses for cancer therapeutics, including (i) IgG1, (ii) IgG2, 3, and 4, (iii) recent findings on Fc receptor functions, and (iv) future directions of reprogramming the constant region of IgG to maximize the efficacy of antibody drug molecules in cancer patients.

Original languageEnglish
Article number382
JournalBiomolecules
Volume10
Issue number3
DOIs
Publication statusPublished - 2020 Mar

Keywords

  • Cancer therapy
  • Fc receptors
  • Immunoglobulin G
  • Therapeutic antibodies

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Fingerprint Dive into the research topics of 'Reprogramming the constant region of immunoglobulin g subclasses for enhanced therapeutic potency against cancer'. Together they form a unique fingerprint.

  • Cite this